The BSPRY (B-box and SPRY domain-containing) antibody is a research tool targeting the BSPRY protein, encoded by the BSPRY gene in humans. This protein belongs to the SPRY domain-containing family, characterized by structural motifs involved in protein-protein interactions and cellular signaling regulation. BSPRY is particularly noted for its role in modulating fibroblast growth factor (FGF) receptor signaling pathways, which influence cell proliferation, differentiation, and survival. Studies suggest its involvement in organ development, including kidney and salivary gland formation, where it may act as a negative regulator to fine-tune FGF signaling activity.
Antibodies against BSPRY are utilized to investigate its expression patterns, subcellular localization, and interactions in both physiological and pathological contexts. Aberrant BSPRY expression has been linked to diseases such as cancer, with evidence pointing to its tumor-suppressive potential in certain malignancies. For example, reduced BSPRY levels correlate with poor prognosis in renal and colorectal cancers. Additionally, BSPRY antibodies aid in exploring genetic disorders linked to FGF signaling dysregulation. As a reagent, these antibodies support Western blotting, immunohistochemistry, and immunofluorescence, enabling researchers to dissect BSPRY's molecular mechanisms and therapeutic relevance. Ongoing studies continue to uncover its broader roles in cellular homeostasis and disease pathogenesis.